advanced stage cancer metastasis
Conditions
Interventions
Transcutaneous pulsed radiofrequency (tPRF) treatment is non-invisave and
painless. It has been used as a pain-relief procedure with no known
complications or side effects.
tPRF will be applied eve
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1) >= 18 years of age; 2) patients with advanced-stage colorectal, breast, prostate or ovarian cancer; 3) presently no longer responding to systemic treatment, and no other standard oncological treatment can be applied anymore (i.e. a patient is strictly in a clear palliative trajectory). 4) history of tumor marker corresponding with disease progression on imaging; 5) history of tumor marker responding to previous oncological treatment; 6) patients able and willing to give written informed consent and comply with the requirement of the study protocol; 7) life expectancy at least 3 months.
Exclusion criteria
Exclusion criteria: 1) treatment with any cancer therapy, including but not limited to chemotherapy and radiation therapy, within 4 weeks before baseline; 2) in the use of critical measuring devices, large metal implants or active implants like a pacemaker; 3) pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor markers - Carcinoembryonic antigen (CEA) for colorectal cancer; - Carcinoma antigen 15.3 (CA15.3) for breast cancer; - Prostate-specific antigen(PSA) for prostate cancer: - Carcinoma antigen 125 (CA125) for ovarian Cancer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain intensity will be assessed using numeric rating scale (NRS); Quality of Life (QOL) will be assessed by -EORTC quality of life questionnaires QLQ-C30 and cancer-specific module; -Edmonton Symptom Assessment System (ESAS). | — |
Countries
Netherlands
Outcome results
None listed